Comparative Pharmacology
Head-to-head clinical analysis: ADRUCIL versus RASUVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADRUCIL versus RASUVO.
ADRUCIL vs RASUVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorouracil (5-FU) is a pyrimidine analog that inhibits thymidylate synthase, interfering with DNA synthesis. It is metabolized to its active metabolites, which incorporate into RNA and DNA, causing cytotoxicity primarily in S-phase cells.
RASUVO is a biosimilar of adalimumab, a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFα) and neutralizes its biological activity by blocking its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecule expression and cytokine release.
12 mg/kg IV bolus daily for 4 days, then if no toxicity, 6 mg/kg IV on days 6, 8, 10, and 12; or 15 mg/kg IV weekly; or 500-600 mg/m2 IV every 3-4 weeks.
Subcutaneous injection: 200 mg once weekly.
None Documented
None Documented
Biphasic elimination: initial t1/2α ~10-20 minutes, terminal t1/2β ~20-24 hours. Accumulation occurs with continuous infusion.
Approximately 11-17 days (mean 13 days); supports every-4-week dosing interval for methotrexate-naive patients and every-4-week or every-2-week dosing in combination with methotrexate.
Primarily hepatic metabolism; renal excretion of metabolites accounts for ~60-80% of the dose. Unchanged fluorouracil excreted renally is <10%. Fecal excretion is minimal (<5%).
Primarily cleared via proteolysis; renal and fecal excretion of active drug minimal. No specific biliary or renal excretion as a percentage.
Category C
Category C
Antimetabolite
Antimetabolite